Education
About Us
Working with TipRanks
Follow Us
Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
RESEARCH TOOLSreports
Total Valuation
Argenica Therapeutics Ltd has a market cap or net worth of ―. The enterprise value is AU$23.55M.
Market Cap―
Enterprise ValueAU$23.55M
Share Statistics
Argenica Therapeutics Ltd has 128,092,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding128,092,850
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Argenica Therapeutics Ltd’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -29.43%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-29.43%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Argenica Therapeutics Ltd is -14.25. Argenica Therapeutics Ltd’s PEG ratio is 12.57.
PE Ratio-14.25
PS Ratio0.00
PB Ratio4.28
Price to Fair Value5.60
Price to FCF-9.95
Price to Operating Cash Flow-9.95
PEG Ratio12.57
Income Statement
In the last 12 months, Argenica Therapeutics Ltd had revenue of 2.60M and earned -5.48M in profits. Earnings per share was -0.05.
Revenue2.60M
Gross Profit2.60M
Operating Income-5.67M
Pretax Income-7.57M
Net Income-5.48M
EBITDA-1.90M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -5.10M and capital expenditures 0.00, giving a free cash flow of -5.10M billion.
Operating Cash Flow-5.10M
Free Cash Flow-5.10M
Free Cash Flow per Share-0.04
Dividends & Yields
Argenica Therapeutics Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.53
52-Week Price Change-13.58%
50-Day Moving Average0.74
200-Day Moving Average0.73
Relative Strength Index (RSI)37.82
Average Volume (3m)106.13K
Important Dates
Argenica Therapeutics Ltd upcoming earnings date is Aug 20, 2025, TBA Not Confirmed.
Last Earnings DateFeb 11, 2025
Next Earnings DateAug 20, 2025
Ex-Dividend Date―
Financial Position
Argenica Therapeutics Ltd as a current ratio of 6.75, with Debt / Equity ratio of 0.00%
Current Ratio6.75
Quick Ratio6.75
Debt to Market Cap0.00
Net Debt to EBITDA8.39
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Argenica Therapeutics Ltd has paid -2.09M in taxes.
Income Tax-2.09M
Effective Tax Rate0.28
Enterprise Valuation
Argenica Therapeutics Ltd EV to EBITDA ratio is -32.75, with an EV/FCF ratio of -12.28.
EV to Sales23.92
EV to EBITDA-32.75
EV to Free Cash Flow-12.28
EV to Operating Cash Flow-12.28
Balance Sheet
Argenica Therapeutics Ltd has AU$15.08M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -AU$15.08M billion.
Cash & Marketable SecuritiesAU$15.08M
Total DebtAU$0.00
Net Cash-AU$15.08M
Net Cash Per Share-AU$0.12
Tangible Book Value Per ShareAU$0.13
Margins
Gross margin is 100.00%, with operating margin of -218.30%, and net profit margin of -210.92%.
Gross Margin100.00%
Operating Margin-218.30%
Pretax Margin-291.34%
Net Profit Margin-210.92%
EBITDA Margin-73.04%
EBIT Margin-291.34%
Analyst Forecast
The average price target for Argenica Therapeutics Ltd is AU$1.19, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$1.19
Price Target Upside70.00% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast6.81%